ATE128864T1 - Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak. - Google Patents

Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak.

Info

Publication number
ATE128864T1
ATE128864T1 AT89912045T AT89912045T ATE128864T1 AT E128864 T1 ATE128864 T1 AT E128864T1 AT 89912045 T AT89912045 T AT 89912045T AT 89912045 T AT89912045 T AT 89912045T AT E128864 T1 ATE128864 T1 AT E128864T1
Authority
AT
Austria
Prior art keywords
treatment
tobacco
elimination
composition
symptoms caused
Prior art date
Application number
AT89912045T
Other languages
English (en)
Inventor
Richard J Wurtman
Judith J Wurtman
Bonnie Spring
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE128864T1 publication Critical patent/ATE128864T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT89912045T 1988-10-26 1989-10-25 Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak. ATE128864T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/262,625 US4999382A (en) 1988-10-26 1988-10-26 Compositions for treating tobacco withdrawal symptoms and methods for their use

Publications (1)

Publication Number Publication Date
ATE128864T1 true ATE128864T1 (de) 1995-10-15

Family

ID=22998317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89912045T ATE128864T1 (de) 1988-10-26 1989-10-25 Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak.

Country Status (7)

Country Link
US (1) US4999382A (de)
EP (1) EP0440704B1 (de)
JP (1) JP2997280B2 (de)
AT (1) ATE128864T1 (de)
CA (1) CA2001572C (de)
DE (1) DE68924537T2 (de)
WO (1) WO1990004387A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0415612T3 (da) * 1989-08-30 1993-12-13 Pfizer Anvendelse af sertralin til behandling af afhængigheder af kemiske stoffer
US5455254A (en) * 1991-02-15 1995-10-03 Mondadori; Cesare Substituted benzofuranylpiperidine as a nootropic agent
DK36391D0 (da) * 1991-03-01 1991-03-01 Lundbeck & Co As H Anvendelse af piperidylsubstituerede indolderivater til behandling af stofmisbrug
BE1005200A3 (fr) * 1991-08-27 1993-05-25 Vandendael Kathleen Mariette Utilisation de tryptophane et composition nutritionnelle comprenant du tryptophane.
AU2446895A (en) * 1994-04-22 1995-11-16 Assistance Publique - Hopitaux De Paris Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
JP3839049B2 (ja) * 1994-06-03 2006-11-01 テムド トラスト メタ位置換のアリルアルキルアミン類ならびに治療および診断のためのその使用
US6004990A (en) * 1994-06-03 1999-12-21 Zebra Pharmaceuticals Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor
BR9501972A (pt) * 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
NZ309980A (en) 1995-06-07 2001-06-29 Noven Pharma Transdermal composition containing a blend of one or more polymers, one or more drugs that has a low molecular weight and is liquid at room temperature
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6908631B1 (en) 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US6617361B2 (en) 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
EP1274444B1 (de) * 2000-03-16 2013-05-15 THE McLEAN HOSPITAL CORPORATION Cdp-cholin und uridin zur behandlung von alkoholmissbrauch
IL154378A0 (en) * 2000-08-16 2003-09-17 Upjohn Co Compounds for the treatment of addictive disorders
CN100430066C (zh) * 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
EP1765364A4 (de) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidine, wie z:b: cytidin, bei der behandlung von patienten mit bipolaren störungen
EP1765075A4 (de) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidine, wie z.b. uridin; bei der behandlung von patienten mit manisch-depressiver psychose
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
DE3777805D1 (de) * 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
DE3736974A1 (de) * 1987-10-31 1989-05-11 Troponwerke Gmbh & Co Kg Verwendung von 2-pyrimidinyl-1-piperazin-derivaten

Also Published As

Publication number Publication date
JPH04501413A (ja) 1992-03-12
JP2997280B2 (ja) 2000-01-11
WO1990004387A3 (en) 1990-06-28
EP0440704B1 (de) 1995-10-11
CA2001572C (en) 2001-01-02
WO1990004387A2 (en) 1990-05-03
CA2001572A1 (en) 1990-04-26
DE68924537D1 (de) 1995-11-16
US4999382A (en) 1991-03-12
EP0440704A1 (de) 1991-08-14
DE68924537T2 (de) 1996-08-01

Similar Documents

Publication Publication Date Title
ATE128864T1 (de) Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak.
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
ATE119040T1 (de) Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten.
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
BR9106537A (pt) Composicao para fumar e processo para adicionar nicotina a um material para fumar
DE69724618D1 (de) Mesembrin und verwandte verbindungen enthaltende pharmazeutische zusammensetzungen
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
ATE257386T1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
ATE232384T1 (de) Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
ATE237633T1 (de) Analogen des keratinozytenwachstumfaktors
DE3856295D1 (de) Behandlung des prämenstruellen oder späten lutealsphase-syndroms
ATE7138T1 (de) Verfahren zur herstellung von 1,5-didesoxy-1,5imino-d-glucitol und dessen n-derivaten.
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
JPS567763A (en) 22hydroxymethyll3*4*55trihydroxyypiperidine derivative* its manufacture and use
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE58905111D1 (de) Verfahren und vorrichtung zur herstellung von tabakfolienstuecken aus wiederaufbereitetem tabak.
FR2539625B1 (fr) Compositions alcooliques ou hydroalcooliques contenant des essences naturelles et des derives du benzylidene camphre
DK527186A (da) Bronchodilaterende farmaceutisk praeparat
ATA493176A (de) Verfahren zur herstellung des neuen 4-imino-1.3-diazabicyclo- (3.1.0)-hexan-2-on und seiner physiologisch vertraglichen salze
ES488301A0 (es) Procedimiento para la obtencion de dehidropeptidos
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
CA2002182A1 (en) Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use
ATE130304T1 (de) Neue alpha-glukosidaseinhibitoren.
ATE122886T1 (de) Verwendung von 1,4-dihydropyridin-derivaten in der behandlung von alkoholsucht.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee